New Brunswick, N.J, USA, July 3, 2008 – Senesco Technologies, Inc. ( »Senesco » or the « Company ») (AMEX:SNT) announced today that it has contracted with Polyplus-transfection (Illkirch, France) to supply Polyplus’s « in vivo-jetPEI® » for systemic delivery of Senesco’s combination therapy of siRNA against Factor 5A and a plasmid of the Factor 5A gene.
Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid delivered with « in vivo-jetPEI® » against subcutaneous multiple myeloma tumors in immunodeficient mice.
« This supply agreement will help Senesco move toward the necessary preclinical toxicology study and ultimately the planned clinical trial targeting multiple myeloma, » commented Bruce Galton, Senesco’s President and CEO. « Polyplus’ PEI technology is already being used in clinical oncology trials by other companies and we look forward to working with them and using their technology to deliver our Factor 5A technology. »
« We are proud that Senesco has chosen our delivery system targeting multiple myeloma and that we have an agreement to supply the company according to this agreement » said Joëlle Bloch, CEO of Polyplus-transfection. « We are delighted that our « in vivo-jetPEI® » will be used as delivery vehicle for a combination of siRNA and plasmid DNA in this therapeutic approach. »
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ, USA. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases.
Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners’ products.